Scientists have revealed “exciting” trial results which show using a targeted cancer drug as well as chemotherapy can improve survival rates for some patients with aggressive blood cancer.
The five-year study run by the Cancer Research UK Southampton Clinical Trials Unit found that adding the drug bortezomib meant that certain patients with diffuse large B cell lymphoma (DLBCL) were more likely to remain in remission after treatment and to survive.
